The Potent BACE1 Inhibitor LY2886721 Elicits Robust Central A beta Pharmacodynamic Responses in Mice, Dogs, and Humans.
May, P.C., Willis, B.A., Lowe, S.L., Dean, R.A., Monk, S.A., Cocke, P.J., Audia, J.E., Boggs, L.N., Borders, A.R., Brier, R.A., Calligaro, D.O., Day, T.A., Ereshefsky, L., Erickson, J.A., Gevorkyan, H., Gonzales, C.R., James, D.E., Jhee, S.S., Komjathy, S.F., Li, L., Lindstrom, T.D., Mathes, B.M., Martenyi, F., Sheehan, S.M., Stout, S.L., Timm, D.E., Vaught, G.M., Watson, B.M., Winneroski, L.L., Yang, Z., Mergott, D.J.(2015) J Neurosci 35: 1199-1210
- PubMed: 25609634 
- DOI: 10.1523/JNEUROSCI.4129-14.2015
- Primary Citation of Related Structures:  
4X7I - PubMed Abstract: 
BACE1 is a key protease controlling the formation of amyloid β, a peptide hypothesized to play a significant role in the pathogenesis of Alzheimer's disease (AD). Therefore, the development of potent and selective inhibitors of BACE1 has been a focus ...